Navigation Links
Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:2/25/2009

king doses of 600 mg/day and 360 mg/day. Both patients were taking concomitant medications that can cause seizures. A possible but unwitnessed seizure was reported in a patient taking a dose of 480 mg/day.

"We are pleased to continue to see concordance of data across endpoints -- CTC changes, PSA declines, radiographic findings and time on treatment," said David Hung, M.D., president and chief executive officer of Medivation. "We continue to move forward with clinical development of MDV3100 and expect to seek U.S. Food and Drug Administration approval to advance to a pivotal Phase 3 registration study this year."

The new MDV3100 efficacy and safety data will be presented in a poster session on Friday, February 27 at 11:45 a.m. Eastern Time at the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary Cancers Symposium in Orlando, Fla.

Teleconference/Webcast Details

Dr. Scher will participate in a teleconference and webcast of a slide presentation today at 4:30 p.m. Eastern Time. He will discuss the new MDV3100 data and the recent research regarding the association between changes in the number of CTCs and the prediction of survival and response to treatment in patients with advanced prostate cancer.

To participate in the live call by telephone, please dial 877-719-9810 from the U.S. or +1-719-325-4785 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A slide presentation that will accompany today's teleconference can be accessed via the Web by accessing the webcast and will also be posted as a PDF next to the event listing in the Investor section of the Medivation website. A replay of the webcast will be available on the Company's website for 30 days.

About Prostate Cancer and MDV3100

Prostate canc
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medivation Presents New Data on Dimebons Novel Mechanism of Action
2. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
3. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
4. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
5. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
6. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
8. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
(Date:8/21/2014)... 2014 On Wednesday of last week RENU ... Redox Signaling molecules, became available for purchase in Australia and ... way that RENU 28 works is, if you think about ... the rate of cellular renewal within your body. If you ... that rate of cellular renewal. What RENU 28 does is ...
(Date:8/20/2014)... it that American Indians largely were wiped out by ... tuberculosis brought to the New World by European explorers., ... people lived in the Americas shortly before Europeans arrived, ... European diseases., But new research led by anthropological geneticists ... of the University of Tubingen in Germany indicates the ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... pharmaceutical company with its principal operations in ... it engaged KPMG Huazhen,("KPMG"), a member firm ... firms,affiliated with KPMG International, to assist the ...
... & Company, LLC, a,Boston-based life science investment bank, ... joined the firm as senior advisor. In ... on internal and client-related activities including,merger & acquisition ... focus on biopharmaceutical transactions. "We are delighted ...
... PTNEW YORK, Jan. 13 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... Weiss, the Company,s Chairman and Chief Executive Officer, is ... Healthcare Conference being held in San Francisco.Mr. Weiss, presentation ... 1:00pm PT and will be accessible from the Investor ...
Cached Biology Technology:Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program 2Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program 3Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2
(Date:8/21/2014)... recently published in the journal Carcinogenesis by ... role for the protein adenomatous polyposis coli (APC) in ... deaths in the U.S. , Lead author Kristi Neufeld, ... co-leader of the Cancer Biology program at the KU ... career trying to understand the various activities of APC, ...
(Date:8/21/2014)... North Carolina State University have developed a novel and ... has applications for creating new materials as well as ... new technique allows us to model much larger and ... more quickly," says Nan Li, lead author of a ... NC State,s Department of Materials Science and Engineering. "This ...
(Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... Infectious diseases can spread very rapidly, so quickly ... However, current testing for such diseases can take hours ... Jayne Wu, associate professor of computer science and electrical ... Eda, associate professor of Forestry, Wildlife and Fisheries at ...
... Health, science and medical reporters are invited to register ... Scientific Meeting March 24 at Moscone Center (North), San ... to focus on the results of care-changing investigations that ... options, advance patient care and improve quality of life. ...
... The following highlights summarize research papers that have been recently ... Journal of Geophysical Research-Earth Surface ( JGR-F ), ... Journal of Geophysical Research-Solid Earth ( JGR-B ), and ... In this release: , 1. Effect of ...
Cached Biology News:University of Tennessee researchers invent device to rapidly detect infectious disease 2Media alert: Press registration open for 2012 SIR Annual Scientific Meeting 2AGU Journal highlights - Feb. 29 2012 2AGU Journal highlights - Feb. 29 2012 3AGU Journal highlights - Feb. 29 2012 4AGU Journal highlights - Feb. 29 2012 5AGU Journal highlights - Feb. 29 2012 6AGU Journal highlights - Feb. 29 2012 7AGU Journal highlights - Feb. 29 2012 8AGU Journal highlights - Feb. 29 2012 9
... of Agilent analytical solutions is the 6890N ... (LAN) allows you to share business and ... decision making. Just as its 6890 GC ... and performance needed for research and method ...
... The 6820 GC system combines world-class ... Chemical QA/QC software, Agilents world-renowned support and ... consumables and supplies--a combination that lets you ... decisions based on dependable data. The Agilent ...
... Plus is a small and sensitive ... for both LC and IC. It features ... Pressure Ionization (API) source for outstanding sensitivity ... compatible with existing LC and IC methods, ...
... The CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In ... assay for detection of active caspases in ... research use only. Not for use in ... Situ Caspase Detection Kits use a novel ...
Biology Products: